Reported 2 days ago
AbbVie has lowered its adjusted profit forecast for 2025, anticipating $248 million in acquisition expenses related to milestone payments and R&D costs. This change comes as the company expands its drug pipeline following the patent expiration of its arthritis drug, Humira, in 2023, and recent acquisitions totaling over $20 billion. The new profit expectations for 2025 are between $11.99 and $12.19 per share, down from a previous estimate of $12.12 to $12.32.
Source: YAHOO